When.com Web Search

  1. Ads

    related to: new depression treatments

Search results

  1. Results From The WOW.Com Content Network
  2. Breakthrough antidepressants with fewer side effects could ...

    www.aol.com/finance/breakthrough-antidepressants...

    The number of people with depression has reached new highs—and so has antidepressant use. As Americans are increasingly reaching for pharmaceutical solutions for depression—about one in eight ...

  3. Switching Antidepressants: Safety, Side Effects & Other ... - AOL

    www.aol.com/switching-antidepressants-safety...

    Switching to a new type of antidepressant may help reverse any weight gain you’ve experienced during treatment. Research shows that approximately one-third of people with depression have ...

  4. The Future Of Postpartum Depression Treatment Is Brighter ...

    www.aol.com/future-postpartum-depression...

    The term is fairly new, ... For mild to moderate symptoms, therapy is considered first-line treatment for postpartum depression and anxiety, says Dr. Meltzer-Brody. Well-trained providers ...

  5. Treatment-resistant depression - Wikipedia

    en.wikipedia.org/wiki/Treatment-resistant_depression

    Ketamine has been tested as a rapid-acting antidepressant [22] for treatment-resistant depression in bipolar disorder, and major depressive disorder. [23] Spravato, a nasal spray form of esketamine, was approved by the FDA in 2019 for use in treatment-resistant depression when combined with an oral antidepressant. [24] [25]

  6. Management of depression - Wikipedia

    en.wikipedia.org/wiki/Management_of_depression

    Stephen M. Stahl, renowned academician in psychopharmacology, has stated resorting to a dynamic psychostimulant, in particular, d-amphetamine is the "classical augmentation strategy for treatment-refractory depression". [84] However, the use of stimulants in cases of treatment-resistant depression is relatively controversial. [85] [86]

  7. Aticaprant - Wikipedia

    en.wikipedia.org/wiki/Aticaprant

    Aticaprant, also known by its developmental codes JNJ-67953964, CERC-501, and LY-2456302, is a κ-opioid receptor (KOR) antagonist which is under development for the treatment of major depressive disorder. [2] [3] [4] A regulatory application for approval of the medication is expected to be submitted by 2025. [2] Aticaprant is taken by mouth. [1]

  1. Ads

    related to: new depression treatments